Literature DB >> 15378398

Translocation (1;22)(p36;q11.2) with concurrent del(22)(q11.2) resulted in homozygous deletion of SNF5/INI1 in a newly established cell line derived from extrarenal rhabdoid tumor.

Akiko Misawa1,2, Hajime Hosoi3, Issei Imoto1,2, Tomoko Iehara3, Tohru Sugimoto3, Johji Inazawa4,5,6.   

Abstract

Malignant rhabdoid tumor (MRT) is a highly malignant pediatric cancer, which arises in various sites such as the kidney, brain, and soft tissues. Cytogenetic studies have revealed alterations of 22q11 in MRT. Recently, deletions and mutations of the SNF5/INI1 locus in 22q11.2 have been reported in MRT, suggesting that SNF5/INI1 is a tumor suppressor gene for MRT. Here we report our molecular cytogenetic study for a newly established cell line from extrarenal MRT with t(1;22)(p36;q11.2). Consequently, the reciprocal translocation was associated with the interstitial deletion of a small segment including SNF5/INI1, and another, chromosome 22, showed terminal deletion, the breakpoint of which was located 70-80 kb centromeric to SNF5/INI1, resulting in homozygous deletion of SNF5/INI1 in this cell line.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378398     DOI: 10.1007/s10038-004-0191-y

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  10 in total

1.  Identification of amplified DNA sequences on double minute chromosomes in a leukemic cell line KY821 by means of spectral karyotyping and comparative genomic hybridization.

Authors:  Y Ariyama; T Sakabe; T Shinomiya; T Mori; Y Fukuda; J Inazawa
Journal:  J Hum Genet       Date:  1998       Impact factor: 3.172

2.  hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.

Authors:  M F Rousseau-Merck; I Versteege; I Legrand; J Couturier; A Mairal; O Delattre; A Aurias
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

3.  Analysis of chromosome 22q as an aid to the diagnosis of rhabdoid tumor: a case report.

Authors:  J Simons; I Teshima; M Zielenska; V Edwards; G Taylor; J Squire; P Thorner
Journal:  Am J Surg Pathol       Date:  1999-08       Impact factor: 6.394

4.  The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors.

Authors:  Jaclyn A Biegel; Ganjarn Kalpana; Erik S Knudsen; Roger J Packer; Charles W M Roberts; Carol J Thiele; Bernard Weissman; Malcolm Smith
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

5.  Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.

Authors:  Jaclyn A Biegel; Lu Tan; Fan Zhang; Luanne Wainwright; Pierre Russo; Lucy B Rorke
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

6.  Cytogenetic and molecular analysis of a t(1;22)(p36;q11.2) in a rhabdoid tumor with a putative homozygous deletion of chromosome 22.

Authors:  C Rosty; M Peter; J Zucman; P Validire; O Delattre; A Aurias
Journal:  Genes Chromosomes Cancer       Date:  1998-02       Impact factor: 5.006

7.  Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.

Authors:  Kaoru Uno; Junko Takita; Kinji Yokomori; Yukichi Tanaka; Shigeru Ohta; Hiroyuki Shimada; Floyd H Gilles; Kanji Sugita; Satoshi Abe; Masahiro Sako; Kohei Hashizume; Yasuhide Hayashi
Journal:  Genes Chromosomes Cancer       Date:  2002-05       Impact factor: 5.006

8.  The clinicopathologic spectrum of putative extrarenal rhabdoid tumors. An analysis of 42 cases studied with immunohistochemistry or electron microscopy.

Authors:  D M Parham; D A Weeks; J B Beckwith
Journal:  Am J Surg Pathol       Date:  1994-10       Impact factor: 6.394

9.  Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.

Authors:  Zhi-Kai Zhang; Kelvin P Davies; Jeffrey Allen; Liang Zhu; Richard G Pestell; David Zagzag; Ganjam V Kalpana
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

  10 in total
  5 in total

1.  Transflip mutations produce deletions in pancreatic cancer.

Authors:  Alexis L Norris; Hirohiko Kamiyama; Alvin Makohon-Moore; Aparna Pallavajjala; Laura A Morsberger; Kurt Lee; Denise Batista; Christine A Iacobuzio-Donahue; Ming-Tseh Lin; Alison P Klein; Ralph H Hruban; Sarah J Wheelan; James R Eshleman
Journal:  Genes Chromosomes Cancer       Date:  2015-05-29       Impact factor: 5.006

2.  Integrated analysis of genes encoding ATP-dependent chromatin remodellers identifies CHD7 as a potential target for colorectal cancer therapy.

Authors:  Xingyan Zhang; Yaoyao Zhou; Zhenyu Shi; Zhenfeng Liu; Hao Chen; Xiaochen Wang; Yiming Cheng; Lishan Xi; Xuanyuan Li; Chunze Zhang; Li Bao; Chenghao Xuan
Journal:  Clin Transl Med       Date:  2022-07

3.  Induction of functional Brm protein from Brm knockout mice.

Authors:  Kenneth W Thompson; Stefanie B Marquez; Li Lu; David Reisman
Journal:  Oncoscience       Date:  2015-04-18

4.  The metabolic addiction of cancer stem cells.

Authors:  Om Saswat Sahoo; Karthikeyan Pethusamy; Tryambak P Srivastava; Joyeeta Talukdar; Mohammed S Alqahtani; Mohamed Abbas; Ruby Dhar; Subhradip Karmakar
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

5.  CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor.

Authors:  S Nodomi; K Umeda; S Saida; T Kinehara; T Hamabata; T Daifu; I Kato; H Hiramatsu; K-I Watanabe; Y Kuwahara; T Iehara; S Adachi; E Konishi; T Nakahata; H Hosoi; T Heike
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.